Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK

CONCLUSION: This study highlights the economic value of rimegepant which was found to be cost-effective for the acute treatment of migraine in adults unsuitable for triptans.PMID:38590236 | DOI:10.1080/13696998.2024.2340932

Source: Journal of Medical Economics - April 9, 2024 Category: Health Management Authors: Karissa Johnston Lauren C Powell Evan Popoff Gil J L'Italien Robert Pawinski Aideen Ahern Sam Large Thang Tran Aaron Jenkins Source Type: research